SAPIEN X4 THV
Symptomatic, severe, calcific aortic stenosis
Key Facts
About Edwards Lifesciences
Edwards Lifesciences is a patient-centric, global medical technology leader exclusively focused on structural heart disease solutions following its strategic 2024 divestiture of its Critical Care business. The company's mission is to deliver life-changing innovations, anchored by its dominant SAPIEN transcatheter aortic valve replacement (TAVR) platform, which has defined the standard of care. Its strategy involves reinvesting capital from the divestiture into R&D and clinical trials to expand indications, penetrate new geographies, and solidify its leadership in high-growth transcatheter mitral, tricuspid, and heart failure markets.
View full company profileAbout Edwards Lifesciences
Edwards Lifesciences is a patient-centric, global medical technology leader exclusively focused on structural heart disease solutions following its strategic 2024 divestiture of its Critical Care business. The company's mission is to deliver life-changing innovations, anchored by its dominant SAPIEN transcatheter aortic valve replacement (TAVR) platform, which has defined the standard of care. Its strategy involves reinvesting capital from the divestiture into R&D and clinical trials to expand indications, penetrate new geographies, and solidify its leadership in high-growth transcatheter mitral, tricuspid, and heart failure markets.
View full company profile